OBJECTIVE: To assess the clinical value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. METHODS: Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. RESULTS: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months. CONCLUSION: FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.
OBJECTIVE: To assess the clinical value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects. METHODS:Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse. RESULTS: A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months. CONCLUSION:FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.
Authors: Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-10 Impact factor: 9.236
Authors: S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone Journal: Arthritis Care Res (Hoboken) Date: 2012-11 Impact factor: 4.794
Authors: Martin A Walter; Ralph A Melzer; Christian Schindler; Jan Müller-Brand; Alan Tyndall; Egbert U Nitzsche Journal: Eur J Nucl Med Mol Imaging Date: 2005-03-04 Impact factor: 9.236
Authors: Joseph J Maleszewski; Brian R Younge; John T Fritzlen; Gene G Hunder; Jorg J Goronzy; Kenneth J Warrington; Cornelia M Weyand Journal: Mod Pathol Date: 2017-03-03 Impact factor: 7.842
Authors: Tanaz A Kermani; Sehriban Diab; Antoine G Sreih; David Cuthbertson; Renée Borchin; Simon Carette; Lindsy Forbess; Curry L Koening; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Robert F Spiera; Kenneth J Warrington; Steven R Ytterberg; Carol A Langford; Peter A Merkel; Nader A Khalidi Journal: Semin Arthritis Rheum Date: 2018-05-09 Impact factor: 5.532
Authors: Shubhasree Banerjee; Mohammadhadi Bagheri; Veit Sandfort; Mark A Ahlman; Ashkan A Malayeri; David A Bluemke; Jianhua Yao; Peter C Grayson Journal: Semin Arthritis Rheum Date: 2018-09-17 Impact factor: 5.532
Authors: Ming Lei; Jian-Zhang Pan; Guang-Ming Xu; Pei-Zhen Du; Mei Tian; Hong Zhang Journal: J Zhejiang Univ Sci B Date: 2019 Nov. Impact factor: 3.066
Authors: Kaitlin A Quinn; Joel S Rosenblum; Casey A Rimland; K Bates Gribbons; Mark A Ahlman; Peter C Grayson Journal: Semin Arthritis Rheum Date: 2019-07-24 Impact factor: 5.532